Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

How Regenerative Therapy Is Helping Fight the Spread of Coronavirus

June 1, 2024 By Cade Hildreth, Founder & President Leave a Comment

Are you worried about the impact coronavirus might have on your health, as well as your family’s health? Are you worried that an effective vaccine may still be a year away?

Coronavirus has already had a horrible impact on people in countries around the world — even those who are young and healthy. The virus hasn’t gone away like many people first thought it would. It now looks like it’s here to stay.

While we wait for vaccine development, a unique approach is showing potential for the treatment of COVID-19 related complications: regenerative therapy. [Read more…]

Gameto Announces New Data Demonstrating Clinical-Grade Manufacturing of In Vitro Maturation Solution for Fertility Care

May 29, 2024 By Cade Hildreth, Founder & President Leave a Comment

Manuscript demonstrates Gameto’s manufacturing process resulted in ovarian support cells of improved efficacy, quality and safety for in vitro maturation applications

NEW YORK, May 8, 2024 — Gameto, a female-led biotechnology company with a mission to redefine women’s healthcare, announced new research outlining the cellular engineering and manufacturing techniques underlying Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) to mature eggs outside of the body. These data underscore that Gameto’s quality by design strategic product development supports the manufacturing of OSC-IVM for clinical and commercial use. [Read more…]

Further CYP-001 GvHD Clinical Data Published in Nature Medicine

May 22, 2024 By Cade Hildreth, Founder & President Leave a Comment

Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60%

Melbourne, Australia; 22 May 2024 — Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data of CYP-001 in patients with steroid-resistant acute graft versus host disease (SR-aGvHD) in the prestigious peer-reviewed journal Nature Medicine.

CYP-001 is Cynata’s Cymerus™ off-the-shelf iPSC^[i]-derived MSC^[ii] product for intravenous infusion, which is being investigated as a potential immune modulating treatment. [Read more…]

Bayer and Evotec to Develop Precision Cardiology Therapeutics Using iPSC-based Disease Modelling

May 10, 2024 By Cade Hildreth, Founder & President Leave a Comment

Bayer and Evotec Update Focus of their Collaboration to Cardiovascular Diseases

Strategic Alliance will Leverage Human iPSC Disease Modelling for Identification of Novel Targets

Berlin and Hamburg, Germany, 30 April 2024 – Bayer and the German-based life science company, Evotec, announced today that they have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases (CVDs). [Read more…]

AABB Releases New Resources and Initiatives For its Certified Advanced Biotherapies Professional (CABP) Program

May 9, 2024 By Cade Hildreth, Founder & President Leave a Comment

May 1, 2024, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce several new offerings as part of its Certified Advanced Biotherapies Professional (CABP) credentialing program. These updates, released to make the CABP program more accessible to biotherapies professionals and organizations, include: [Read more…]